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ADEQUATE DISCLOSURES IN 140 CHARACTERS OR LESS—
ANALYSIS OF HOW ENDORSERS SHOULD APPROACH
ADVERTISING ON A PLATFORM WITH CHARACTER
LIMITATIONS
Jacob Hughey
ABSTRACT
Social media websites such as Twitter and Facebook have transformed the
way businesses and individuals market their products and services. These
websites have given advertisers and promoters the ability to advertise directly
to consumers who would most likely be interested in their products or services.
In theory, this should benefit both the consumer and the owner of the product
or provider of the service. The product owner or service provider can more
efficiently use its marketing resources, and consumers will be exposed to
advertisements of products and services catered to their interests. This
increased ability to target specific consumers, however, brings an increased
risk of consumer deception. After recognizing this increased risk, several
federal agencies empowered to protect the consumer from deceptive trade
practices have published guidance on how to proceed to communicate an
advertisement on social media sites to avoid the risk of deception. This
seemingly premature application of consumer law to these websites has created
many problems and concerns. Many of these sites have character space
limitations, “CLP’s”, which would restrict the ability of businesses to
effectively communicate an advertisement while also providing the necessary
disclosure requirements. While it is clear that these agencies are not excluding
these mediums from disclosure requirements, which is where the clarity ends.
This Article is focused on highlighting the major issues that arise for
advertisers, consumers and promoters that are using social media sites. It also
addresses common themes in each of the agencies’ guides concerning the use
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an effort to expose problems created by social media.

12/10/2015 9:17 AM

2

EMORY CORPORATE GOVERNANCE AND ACCOUNTABILITY REVIEW [Vol. 3

of social media websites and makes an effort to interpret a very unclear area of
law.
INTRODUCTION
“If there is one thing more dishonest than dodgy marketing, it is the pretense
that marketing raises no ethical concerns. The truth is that marketing raises
enormous ethical questions every day—at least it does if you are doing it
right.”
—Rory Sutherland, Vice-Chairman, Ogilvy Group UK.1
Rather than communicate this message through Twitter, Rory made this
statement in an article posted on a marketing blog site. Which makes sense,
because if Rory attempted to convey this message through Twitter it would
look like this:
“If there is one thing more dishonest than dodgy marketing, it is the pretense
that marketing raises no ethical concerns. The truth is that”
Like many social media sites, Twitter has character limitation requirements
imposed on messages conveyed through its website. In order for Rory to
effectively communicate his message he would have to create two separate
tweets, shorten the length of his message, or provide a hyperlink that directs
his followers to his full quotation on a separate website. So while Rory might
be annoyed, he has different options to choose from as to how he would like to
convey his message.
Suppose that rather than posting a favorite quote on Twitter, Rory wanted
to express how satisfied he is with his new blood pressure medication called
“HEARTLY.” So with little premeditation, Rory promptly pulls out his mobile
phone and publishes the following tweet:
“Luv my new BP med. Feeling like a million bucks. #blessed #HEARTLY”
While this is a clear endorsement of the drug HEARTLY, Rory is not under
contract to promote HEARTLY, and his Twitter followers would not be misled
if they assumed that this was Rory’s truthful opinion and experience with the
drug.

1 Rory Sutherland, We Can’t Run Away from the Ethical Debates in Marketing, MARKETING SOCIETY:
THE LIBRARY (July 9, 2012), https://www.marketingsociety.com/the-library/we-cant-run-away-ethicaldebates-marketing.
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Let’s change the facts again. Let’s assume that Rory is not a person but
actually an advertiser of the drug HEARTLY. Now if Rory makes the same
statement about the drug HEARTLY, Rory’s statement is transformed from an
opinion into an advertisement subject to FDA regulations. These regulations
would require an advertisement of a blood pressure medication such as
HEARTLY to contain certain disclosures about the risks of using HEARTLY.
The FDA has made it clear that advertisements conveyed through platforms
such as Twitter are not exempt from these disclosures. Accordingly, any
message without these disclosures would subject Rory and other parties
involved with the drug HEARTLY to liability.
Once more we change the facts and assume Rory is a male celebrity who
uses HEARTLY and sincerely enjoys the benefits that he has experienced
using HEARTLY. Rory also has an endorsement deal with HEARTLY and
makes a commission based on the amount of HEARTLY sold each month.
Rory wants to publish the following message on his Twitter:
“Luv HEARTLY- BEST BP drug ever”
This poses a problem for Rory as well as the marketing team of
HEARTLY. This tweet would be considered an endorsement of a product by
an individual with a material connection between himself and the drug. While
this tweet is Rory’s honest and truthful opinion about HEARTLY, the fact that
Rory is benefiting from the sale of the drug must be disclosed to prevent
consumer deception. Despite there being no evidence of Rory’s intent to
mislead his followers, the federal agencies created to protect consumers are not
concerned with the subjective intent of the endorser. Their focus is on how the
consumer perceives the message.2 This poses the question of how much
disclosure is necessary to prevent liability. Would it be sufficient to just
disclose the material connection that the celebrity has in the message with an
#Ad or similar abbreviation? Or is the celebrity also required to comply with
the disclosure requirements provided by the FDA regarding the prescription
drug HEARTLY in 140 characters or less?
The answer is unclear. In an effort to comply with disclosure requirements
while marketing on these Character Limited Platforms (“CLP’s”), many

2 See FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising, 74 Fed. Reg.
53,124, 53,125 (Oct. 15, 2009) (to be codified at 16 C.F.R. pt. 255) (“The guides of the FTC have always
defined ‘endorsements’ by focusing on the message consumers take from the speech at issue.”) [hereinafter
Advertising Guides].
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businesses and individuals have asked for guidance from consumer protection
agencies on how they should approach advertising on CLP’s like Twitter.3 In
response to their pleadings, these agencies have published and edited previous
guidance documents that attempt to address how advertisers should approach
marketing on CLP’s.4 While each agency was created with a different purpose,
many of their responsibilities with regard to consumer protection overlap. The
published guides have similar messages and themes. For example, they each
make it clear that CLP’s are not exempt from disclosure requirements.5 Many
times a simple #AD or hyperlink is not sufficient disclosure, and if the required
disclosure in the message does not fit the CLP’s space requirements, the
advertisement should not be published on that platform.6
I. THE RISE OF SOCIAL MEDIA AND ITS EFFECT ON MARKETING
A. Definition of Social Media
There have been many definitions of social media and what it entails. So
for the purpose of this Article, it will be defined broadly as provided by the
FFIEC:

3 See U.S. FOOD AND DRUG ADMIN., FOR INDUSTRY: USING SOCIAL MEDIA, http://www.fda.gov/
AboutFDA/CentersOffices /OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm (last updated Oct.
29, 2014) (FDA gathering input necessary to “provide guidance on the promotion of FDA-regulated medical
products using the Internet and social media tools.”); Social Media: Consumer Compliance Risk Management
Guidance, 78 Fed. Reg. 4,848-01 (Jan. 23, 2013) (inviting comments on the “application of consumer
protection laws and regulations within the realm of social media.”). See, e.g., Pradnya Joshi, Approval by a
Blogger May Please a Sponsor, N.Y. TIMES (July 12, 2009), http://www.nytimes.com/2009/07/13/technology/
internet/13blog.html (discussing the increasing prevalence of online endorsements and the blurred line
between personal opinion and advertising).
4 See FED. TRADE COMM’N, FTC STAFF REVISES ONLINE ADVERTISING DISCLOSURE GUIDELINES,
(Mar. 12, 2013), https://www.ftc.gov/news-events/press-releases/2013/03/ftc-staff-revises-online-advertisingdisclosure-guidelines; Thomas Abrams, FDA Issues Draft Guidances for Industry on Social Media and
Internet Communications About Medical Products: Designed with Patients in Mind, U.S. FOOD AND DRUG
ADMIN.: FDA VOICE (June 17, 2014), http://blogs.fda.gov/fdavoice/index.php/2014/06/fda-issues-draftguidances-for-industry-on-social-media-and-internet-communications-about-medical-products-designed-withpatients-in-mind/; FED. FIN. INST. EXAMINATION COUNCIL, FINANCIAL REGULATORS ISSUE FINAL GUIDANCE
ON SOCIAL MEDIA, (Dec. 11, 2013), https://www.ffiec.gov/press/pr121113.htm.
5 Compare U.S. FOOD & DRUG ASS’N, GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA PLATFORMS
WITH CHARACTER SPACE LIMITATIONS, at 5 (June 18, 2014), http://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm401087.pdf [hereinafter FDA Guides], with FED.
FIN. INST. EXAMINATION COUNCIL, SOCIAL MEDIA: CONSUMER COMPLIANCE RISK MANAGEMENT GUIDANCE,
at 8 (Dec. 11, 2003) https://www.ffiec.gov/press/PDF/2013_Dec%20Final%20SMG%20attached%20to%2011
Dec13%20press%20release.pdf.
6 See FED. TRADE COMM’N, supra note 4; FDA Guides, supra note 5 at 5.
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Social media is considered to be a form of interactive online
communication in which users can generate and share content
through text, images, audio, and/or video. Social media can
take many forms, including, but not limited to, microblogging sites (e.g. Facebook, Google Plus, MySpace, and
Twitter); Forums, blogs, customer review websites and
bulletin boards (e.g. Yelp); photo and video sites (e.g., Flickr
and YouTube); sites that enable professional networking
(e.g., LinkedIn); virtual worlds (e.g., Second Life); and social
games (e.g., FarmVille and CityVille).7
The FFIEC states that, “social media can be distinguished from other
online media in that communication tends to be more interactive.”8 It is this
interaction between businesses and consumers that generates concerns in the
world of advertising. When used properly, social media can be an extremely
efficient and effective communication method that provides benefits for both
consumers and producers alike.9 However, the informality of a message
communicated though this medium creates an inherent risk of deception.
For example, a drug manufacturer was recently issued a formal warning
letter by the FDA for a deceptive ad posted by social media maven Kim
Kardashian.10 With more than forty-eight million followers,11 Kardashian is
one of the most followed people on Instagram and is often paid by companies
to endorse products.12 The Instagram post at issue was a picture of Kardashian
holding a bottle of the morning sickness medication, Diclegis, while making
one of her signature selfie faces.13 The caption attached to the filtered photo
was a glowing review about the positive effects of the drug, and a claim that

7 Social Media: Consumer Compliance Risk Management Guidance, FDIC FIL-56-13 (2013), 2013 WL
6515995 at pt. II.
8 Id.
9 See Jason DeMers, The Top 10 Benefits of Social Media Marketing, FORBES (Aug. 11, 2014, 12:24
PM), http://www.forbes.com/sites/jaysondemers/2014/08/11/the-top-10-benefits-of-social-media-marketing/.
10 Thomas M. Burton, FDA Sends Warning Letter After Kim Kardashian Touts Morning Sickness Drug,
WALL ST. J (Aug. 12, 2015), http://www.wsj.com/articles/fda-sends-warning-letter-after-kim-kardashian-toutsmorning-sickness-drug-1439401985.
11 Kim Kardashian (@kimkardashian), INSTAGRAM, https://instagram.com/kimkardashian/ (last visited
Oct. 18, 2015).
12 See Caitlin O’Toole, Kim Kardashian: The Queen of Endorsements, WETPAINT (Dec. 7, 2011),
http://www.wetpaint.com/kim-kardashian-the-queen-of-endorsements-698802/.
13 Ashlee Kieler, After FDA Warning, Kim Kardashian Posts Corrected Endorsement of Morning
Sickness Pill, CONSUMERIST (Aug. 31, 2015), http://consumerist.com/2015/08/31/after-fda-warning-kimkardashian-posts-corrected-endorsement-of-morning-sickness-pill/.
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“there was no increased risk to the baby” when taking the morning sickness
medication.14 In its formal warning letter to the drug’s manufacturer,
Duchesnay USA, the FDA stated the endorsement was deceptive because it
failed to communicate any risk information. This is especially problematic on a
public policy level because it “suggest[s] that Diclegis is safer than has been
demonstrated.”15 In response to the FDA’s warning, Kardashian deleted the
original post and replaced it with the following caption:
#CorrectiveAd I guess you saw the attention my last
#morningsickness post received. The FDA has told Duchesnay, Inc.,
that my last post about Diclegis (doxylamine succinate and
pyridoxine HCl) was incomplete because it did not include any risk
information or important limitations of use for Diclegis. A link to this
information accompanied the post, but this didn’t meet FDA
requirements. So, I’m re-posting and sharing this important
information about Diclegis….”16

The post went on to list important safety information such as allergy
concerns, common side effects, and a link to a website created by Duchesnay
USA with more information about the drug.17 The new caption was in
compliance with the FDA’s standards, but far exceeded the typical length of an
Instagram post, which for some is nothing more than a few expressive emojis.
The risk of deception through social media advertising can be even greater
when using a social media platform that has a character limitation requirement.
B. Character Limited Platforms (CLP’s)
As demonstrated in the introductory examples, CLP’s are creating
problems in the world of advertising. While many of the examples in the
guides and in this Article involve Twitter, CLP’s are not limited to Twitter.
CLP’s are found on any website that allows users to communicate a message
but limits that communication in some way or another.18 This limitation may
be on how many words a user is allowed to write or how many photos that they
14

See Burton, supra note 10.
Daina B. Solomon, FDA Issues Warning over Kim Kardashian’s Drug Promotions, L.A. TIMES
(Aug. 11, 2015), http://www.latimes.com/business/la-fi-fda-kardashian-20150811-story.html.
16 Josh Wolford, Kim Kardashian Forced to Post a ‘Corrective Ad’ After FDA Called Previous One
Misleading, WEBPRONEWS (Aug. 31, 2015), http://www.webpronews.com/kim-kardashian-forced-to-post-acorrective-ad-after-fda-called-previous-one-misleading-2015-08/.
17 Id.
18 See generally Charlene Kingston, How to Use Twitter for Business and Marketing, SOC. MEDIA
EXAM’R (Apr. 10, 2013), http://www.socialmediaexaminer.com/how-to-use-twitter-for-business-andmarketing/.
15
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are allowed to post. The limitation could be one word or ten thousand words.
Accordingly, any platform that does not allow you to fully communicate your
message is considered a CLP for the purposes of this Article. So while many of
the examples are based on Twitter, the guidance of the agencies can be
applicable to any CLP that limits one’s ability to fully communicate their
message.
II. BRIEF OVERVIEW ON FEDERAL AGENCIES CREATED TO PROTECT THE
CONSUMER
A. Agencies in General
Administrative agencies are created by Congress or the President to carry
out governmental programs.19 While there are many different sources that
regulate and govern the activities of administrative agencies, understanding the
concept of an enabling statute will be sufficient for the purpose of this Article.
An enabling statute specifically empowers an agency to take certain actions
and generally an agency may not act beyond its permissive scope.20 These
enabling statutes typically require the agency to assist the government in the
regulation of a specific industry by gathering data, granting licenses, creating
policy, as well as enforcing and adjudicating disputes.21 When confusion is
voiced over how a regulation should be applied in a specific circumstance, the
agencies will typically publish guidance (“guides”) on how an entity should
proceed.22 While these guides are not legally binding, they are representations
of an agency’s current belief on how one should proceed in complying with its
regulations.23

19

See U.S. Const. art. I, § 1; Administrative Agencies, US LEGAL, http://system.uslegal.com/
administrative-agencies/ (last visited Oct. 25 2015); A Note on Administrative Agencies, THE HERITAGE GUIDE
TO THE CONSTITUTION, http://www.heritage.org/constitution/articles/2/essays/101/a-note-on-administrativeagencies (last visited Oct. 25 2015).
20 See
Administrative Law And Procedure, THEFREEDICTIONARY, http://legal-dictionary.
thefreedictionary.com/Administrative+Law+and+Procedure (last visited Oct. 25 2015); Administrative
Agency, THEFREEDICTIONARY, http://legal-dictionary.thefreedictionary.com/Administrative+Agency.
21 See About Administrative Law, LOYOLA UNIV., http://lawlibguides.luc.edu/content.php?pid=128348
&sid=1101470 (last visited Oct. 25, 2015); Administrative Agencies, supra note 19.
22 See Definitions of Guidance Documents, EPA, http://www2.epa.gov/laws-regulations/definitionsguidance-documents (last visited Oct. 25, 2015).
23 See Jill E. Family, Easing the Guidance Document Dilemma Agency by Agency: Immigration Law and
Not Really Binding Rules, 47 U. MICH. J.L. REFORM 1 (2013), available at http://repository.law.umich.
edu/mjlr/vol47/iss1/1.
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B. Guidance from the FDA and FTC
1. The FDA
The Federal Food, Drug and Cosmetic Act created the U.S. Food and Drug
Administration (“FDA”) in an effort to manage the inherent risks associated
with drugs and other medical devices.24 The FDA has been given very broad
regulatory authority over products associated with food and drugs.25 This broad
regulatory authority inherently gives the FDA the power to protect consumers
from deceptive marketing.26
The FDA is currently in the process of publishing guides specifically
addressing how an advertiser should proceed when utilizing a CLP.27 On June
18, 2014, the FDA posted a draft guidance titled “Internet/Social Media
Platforms with Character Space Limitations: Presenting Risk and Benefit
Information for Prescription Drugs and Medical Devices.”28 The FDA is
currently waiting for additional comments in order to publish an effective
guidance article, and therefore the current draft contains nonbinding
recommendations.29 However, regardless of the binding power of the draft, the
FDA’s specific focus on CLP’s is beneficial to this analysis of advertising on
CLP’s in general. While the FDA does not make its guides with the intention
of providing guidance to industries outside of their authority,30 its analysis, tips
and considerations help us fill in holes left by the FTC’s broad guidance.
2. The FTC
The Federal Trade Commission “FTC” was created on September 26, 1914,
after President Woodrow Wilson signed the Federal Trade Commission Act

24

See 21 U.S.C. § 1705; What We Do, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/AboutFDA/
WhatWeDo/ (last visited Aug. 05, 2014).
25 What Does FDA Regulate?, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/AboutFDA/
Transparency/Basics/ucm194879.htm (last updated June 12, 2014).
26 Id.
27 See FDA Guides, supra note 5.
28 Id.
29 U.S. FOOD & DRUG ASS’N, INTERNET/SOCIAL MEDIA PLATFORMS WITH CHARACTER SPACE
LIMITATIONS—PRESENTING RISK AND BENEFIT FOR PRESCRIPTION DRUGS AND MEDICAL DEVICES: DRAFT
GUIDANCE FOR INDUSTRY (2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory
information/guidances/ucm401087.pdf.
30 U.S. FOOD & DRUG ASS’N, supra note 29, at 1. Page one of the FDA Guides specifically states that the
guides were intended for manufacturers packers and distributors of prescription human and animal drugs and
medical devices for human use.
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(“FTCA”) into law.31 The stated mission of the FTC is to protect consumers
and promote competition in the marketplace.32 The FTCA is the primary
enabling statute of the FTC, and empowers the FTC with the authority to
protect consumers from unfair or deceptive acts affecting commerce.33 It
fulfills its stated purpose through regulation, enforcement, and establishing
requirements that prevent deception.34 Since the creation of the FTC, the
agency has developed policies and regulations aimed at protecting the
consumer and educating entities on their rights and responsibilities in the
marketplace.35
While the FDA guidance is directed at the Food and Drug industry, the
FTC’s focus is much broader and extends to the majority of transactions in the
marketplace.36 The FTC has revised its guides on how an advertiser should
advertise on a CLP.37
The first half of this Article will focus on guidance from the FTC and FDA
on how to portray a non-deceptive message on a CLP. The first guide that we
will examine, “DOT COM Disclosures,” makes an effort to describe details
that businesses should consider while developing advertisements for online
media.38 While the FDA guides give a more detailed analysis of how a

31

Our History, FED. TRADE COMM’N (last visited Mar. 15, 2015), https://www.ftc.gov/about-ftc/our-

history.
32

What We Do, FED. TRADE COMM’N (last visited Mar. 15, 2015), http://www.ftc.gov/about-ftc/what-

we-do.
33 Federal Trade Commission Act, FED. TRADE COMM’N (last visited Mar. 15, 2015), https://www.ftc.
gov/enforcement/statutes/federal-trade-commission-act. What We Do, supra note 32.
34 See Statutes Enforced or Administered by the Commission, FED. TRADE COMM’N (last visited Mar. 15,
2015), http://www.ftc.gov/enforcement/statutes. This is a very general summary of the authority given to the
FTC by the FTCA enabling act. The FTC has published a more specific summary of its powers granted by the
FTCA on their website.
35 Id.; see Rules, FED. TRADE COMM’N (last visited Mar. 15, 2015), http://www.ftc.gov/enforcement/
rules. Commission rules are published in Title 16 of the Code of Federal Regulations. The FTC has provided a
link to the CFR on its website. Competition Advisory Opinions, FED. TRADE COMM’N (last visited Mar. 15,
2015), https://www.ftc.gov/tips-advice/competition-guidance/competition-advisory-opinions. The website also
provides links to other advisory opinions concerning proposed conduct.
36 See Competition Advisory Opinions, supra note 35; supra note 32.
37 The FTC’s Endorsement Guides: What People Are Asking, FED. TRADE COMM’N (last visited Mar. 15,
2015),
https://www.ftc.gov/tips-advice/business-center/guidance/ftcs-endorsement-guides-what-people-areasking.
38 See Press Release, Fed. Trade Comm’n, FTC Staff Revises Online Advertising Disclosure Guidelines: “Dot
Com Disclosures” Guidance Updated to Address Current Online and Mobile Advertising Environment (Mar.
12,
2013),
https://www.ftc.gov/news-events/press-releases/2013/03/ftc-staff-revises-online-advertisingdisclosure-guidelines [hereinafter Dot Com Disclosures].
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marketer should proceed to advertise on a CLP, the FTC guides also address
some of the issues that arise with space-constrained screens.
The second half of this Article addresses the type of disclosure required by
third party endorsements on a CLP. As we will see, an endorser can be an
employee of the company making the product or a celebrity who has
contracted to promote the product. It could prove to be problematic when an
employee or celebrity endorser conveys a message on a CLP without
disclosing the contractual relationship they have with the product’s company.39
The advertiser could be held liable regardless of whether it had any control
over the message.40 While to this date there has been no guidance published
specifically addressing the issue of how much disclosure is required from an
endorser on a CLP, the FTC has revised previous guides regarding
endorsements and has added illustrative examples that include advertising on
social media.41 While the publication of these revisions acted as a declaration
that advertisements conveyed on CLP’s such as Twitter are not exempt from
disclosure requirements, the revisions did very little to address the issue of
when an endorser could be held liable.42 The second part of this Article will
also provide examples and analysis on what is considered an endorsement,
when liability is created, who is liable and when disclosure is required.
III. FTC AND FDA GUIDANCE ON USING A CLP
A. Messages Requiring Disclosures
When deciding what amount of disclosure would be sufficient for any
given message conveyed, an advertiser must first evaluate the language of the
message and decipher whether there is a hidden claim or representation being
communicated; this can be difficult.43 Sometimes an advertiser or endorser’s
loyalty and admiration of the product can lead to an innocent representation
that is actually deceptive in the eyes of a consumer. For example, the FDA
provides an illustration in its guides of a seemingly innocent tweet that is

39

Id.
See 16 C.F.R. § 255.1 (2015).
41 See id. §§ 255.0-255.5.
42 See id. §§ 255.0-255.2, 255.5.
43 See FDA Guides, supra note 5. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory
information/guidances/ucm401087.pdf.
40
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actually a claim in disguise.44 This example involves a fictional drug called
“No Focus” that was created for the purpose of battling mild to moderate
memory loss.45 The firm promoting the product tweets, “No Focus for mild to
moderate memory loss.”46 At first glance, the tweet seems to be an innocent
representation of the drug and its purpose. However, as we will later see, the
FDA would categorize this message as providing “benefit information” and
states that such a message should be followed by sufficient risk information to
avoid consumer deception.47 While similar statements might require less
disclosure outside of the realm of prescription drug and FDA authority,48 this
example illustrates the significance of examining each message thoroughly in
order to find hidden claims or representations that require disclosure to prevent
liability.
B. Messages Not Requiring Disclosures
It bears repeating that the sole purpose of providing a disclosure is to avoid
deceiving the consumer. The FTC makes it clear that in order to decide
whether some form of disclosure is required, the advertiser should view the
message through the eyes of a reasonable consumer.49 Not all messages pose
the inherent risk of consumer deception, and accordingly may require little
disclosure, or in some cases, none at all.50 The FDA notes that mere
“reminder” promotions are exempt from many of the labeling and advertising
disclosure requirements.51 This would suggest that little to no disclosure would
be required if a message can be categorized as a reminder promotion. The FDA
describes a “reminder promotion” as a message that calls attention to the name
of the product but does not make any representations or suggestions about the
44 See U.S. FOOD & DRUG ADMIN., supra note 29. At this point of the Article I am using the FDA’s
example to illustrate the importance of language used on a CLP. The FDA is using this example in its guides to
illustrate how little space is left for disclosing required risk information after using 40 out of the 140 character
maximum for the benefit claim “No focus for mild to moderate memory loss”.
45 Id.
46 Id.
47 Id.
48 As discussed throughout the Article, there are more express disclosure requirements required by the
FDA for products under its regulation due to the risks associated; i.e. if representation about firm’s
prescription drug MUST include certain risk information. See 21 C.F.R. § 202.1(n) (2015), “brief statement of
intended uses” and relevant risk information in restricted-device advertising. See id. § 202.1(r) (2015).
49 Dot Com Disclosures, supra note 38.
50 The FTC notes that under some circumstances, when utilizing a space-constrained advertisement, it
might be acceptable to make the disclosures on a page to which the ad linked. Id. at ii, 10.
51 The FDA is not saying that Disclosure is never required for a “reminder promotion” just that they are
exempt from many of the labeling and advertising disclosure requirements. FDA Guides, supra note 5.
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product.52 Returning to the FDA’s example regarding “No Focus”, disclosure
may not be necessary if it simply stated: “Ask your doctor about No Focus.”53
According to this interpretation of the FDA’s guidance, this tweet would be an
example of a reminder promotion; the firm makes no representations or
misleading claims about the drug. These types of messages do not carry a risk
of deception; they fail to make a representation about their product, and are
only an effective marketing tool after the benefits and risks associated with the
drug are common knowledge and understood by the consumer.54
C. Adequate Disclosures
Once an advertiser decides that the message it would like to portray
requires some form of disclosure to avoid misconception, it should ensure that
the disclosure is adequate.55 The guides provide similar instruction on how an
entity should proceed in ensuring that its disclosure is sufficient to prevent
consumer deception.56 While the guides focus on different aspects of an
adequate disclosure,57 the general themes and analysis required are very
similar. In deciding whether a disclosure is sufficient, an entity should always
ask itself: (i) how much disclosure is needed with my product or service, (ii)
does the benefit information balance with the risk information on my
advertisement58, and (iii) is the disclosure being communicated effectively to
the consumer?
1. FTC Guidance on an Adequate Disclosure
While the FDA is focused on ensuring that certain legally required
disclosures are communicated effectively to the consumer, the FTC is more
52 Reminder Ad, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/Drugs/ResourcesForYou/
Consumers/PrescriptionDrugAdvertising/ucm083573.htm (last visited Mar. 30, 2015) (defining a reminder
advertisement and providing examples).
53 FDA Guidance for Industry, supra note 44.
54 See Reminder Ad, supra note 52.
55 U.S. FOOD & DRUG ADMIN., supra note 29.
56 Id.
57 See U.S. DEP’T OF HEALTH AND HUMAN SERVICES, FOOD AND DRUG ADMIN., BRIEF SUMMARY AND
ADEQUATE DIRECTIONS FOR USE: DISCLOSING RISK INFORMATION IN CONSUMER-DIRECTED PRINT
ADVERTISEMENTS AND PROMOTIONAL LABELING FOR PRESCRIPTION DRUGS (2015); see also Dot Com
Disclosures, supra note 38 (The FDA is able to focus more on how an advertiser should balance disclosures on
a character-limited platform because many of the products that the FDA regulates require certain disclosures
by law. The FTC, on the other hand, does not assume a disclosure is needed and is more concerned with how
the message deceives the consumer).
58 FDA Guides, supra note 5, at 4 (The FDA goes into detail on this balancing test while reviewing an
advertisement on a CLP).
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concerned with the overall risk of deception in the advertisement.59 Disclosures
are required to ensure an advertisement is truthful, not misleading,60
substantiated, and fair.61 The FTC requires that the disclosures satisfy the
“Clear and Conspicuous” requirement.62 It acknowledges that there is no bright
line rule for determining whether a disclosure is clear and conspicuous, but
provides a number of factors that an advertiser should focus on to avoid a
violation.63 While many of the factors may have some effect on how an
advertiser should proceed to advertise on social media CLP’s, this Article is
concentrated on the actual message being portrayed on a CLP such as Twitter.
For the purpose of the first half of this Article, assume that a company is
analyzing how it should articulate the language of an advertisement on Twitter
to avoid deception. Also assume that whatever message the entity conveys will
be easily read on the device being used to view it, and any disclosures within
the message are placed near the ad in a non-conspicuous way.
2. Necessary Disclosures
A popular belief in the world of CLP advertising is that a simple hyperlink
or #AD at the end of an advertisement will effectively prevent an
advertisement from being deemed deceptive.64 The guides are clear that
standing alone, these abbreviated disclosures are insufficient in many
situations.65 Often an advertisement must include necessary disclosures within

59

Id. at 3-5; FED. TRADE COMM’N, THE FTC’S ENDORSEMENT GUIDES: WHAT PEOPLE ARE ASKING

(2013).
60 FED. TRADE COMM’N, FTC POLICY STATEMENT ON DECEPTION (Oct. 14, 1983) (The FTC’s deception
policy describes an ad as deceptive if it contains a statement or omits information that is likely to mislead
consumers acting reasonable under the circumstances and is “material” or important to a consumer’s decision
to buy or use the product.).
61 See Dot Com Disclosures , supra note 38, at 5-6.
62 Id. at 6.
63 Dot Com Disclosures, supra note 38 at 7 (i. “[t]he placement of the disclosure in the advertisement and
its proximity to the claim it is qualifying”; ii. “[t]he prominence of the disclosure”; iii. “[w]hether the
disclosure is unavoidable”; iv. “[t]he extent to which items in other parts of the advertisement might distract
attention”; v. “[w]hether the disclosure needs to be repeated several times in order to be effectively
communicated, or because consumers may enter the site at different locations or travel through the site on
paths that cause them to miss the disclosure”; vi. “[w]hether disclosures in audio messages are presented in an
adequate volume and cadence and visual disclosures appear for a sufficient duration”; and vii. “[w]hether the
language of the disclosure is understandable to the intended audience”).
64 See Benjamin Stein, FTC Updates FAQs on its Endorsement Guides, INFORMATION LAW GROUP
(Oct. 21, 2015), http://www.infolawgroup.com/2015/06/articles/ftc/ftc-updates-faqs-on-its-endorsementguides/; Ann Tran, When To Use #Ad in Your Tweets, ANN TRAN (Oct. 19, 2015), http://ann-tran.com/2014/
04/when-to-use-ad-in-your-tweets/.
65 See Dot Com Disclosures, supra note 38, at 10.
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the message to avoid consumer deception.66 An advertiser must decide if the
disclosure would materially affect a consumer’s decision to purchase a product
or service.67 If so, this disclosure needs to be placed in the advertisement itself
rather than within a hyperlink.68 If an advertiser is unable to fit the disclosure
and the intended message on the CLP, the entity should not use that platform.69
Accordingly, identifying necessary disclosures is one of the most important
preliminary determinations that an advertiser must make when deciding
whether or not to advertise on a CLP.70
An advertiser that creates products as opposed to providing services might
need a disclosure for several reasons. These reasons include warranties
communicated in the message, statements of a product’s condition, and risks
associated with the product.71 The simplest illustration of a “necessary
disclosure” is prescription drugs. The FDA guides note that, at a minimum, the
firm’s message should include the most serious risks associated with the drug
or medical device.72 The FDA describes a serious risk as one that would
include all risks known to be fatal or life threatening, even if they are also
represented on the box of the product.73 It further states that even if a drug does
not have a boxed warning, fatal risks, or contradictions, the most significant
warnings or precautions about the product should still be communicated in the
message.74 This suggests that even products with low inherent risks are
required to provide some type of disclosure in the message itself, outside of the
hyperlink.
Unlike advertisements for products such as pharmaceutical drugs,
advertisements for services are less likely to pose risks for physical injury to
66

Id.
Fed. Deposit. Ins. Corp., FIL-26-2004, Unfair or Deceptive Acts or Practices by State-Chartered
Banks, FDIC (Mar. 11, 2004), available at https://www.fdic.gov/news/news/financial/2004/fil2604.html.
68 Dot Com Disclosures, supra note 38, at 10.
69 Id. at 6–7.
70 FTC- in determining whether the disclosure should be placed in the space-constrained ad itself or on
the website to which the ad links, advertisers should consider how important the information is to prevent
deception, how much information needs to be disclosed, the burden of disclosing it in the ad itself, how much
information the consumer may absorb from the ad, and how effective the disclosure would be if it were made
on the website”. Id. at pt. III C(1)(e). “Evaluating Proximity in Space-Constrained Ads.” Id. at 6.
71 Id. at 10.
72 FED. DRUG AGENCY, GUIDANCE FOR INDUSTRY INTERNET/SOCIAL MEDIA PLATFORMS WITH
CHARACTER SPACE LIMITATIONS—PRESENTING RISK AND BENEFIT INFORMATION FOR PRESCRIPTION DRUGS
AND MEDICAL DEVICES 9 (June 2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory
information/guidances/ucm401087.pdf.
73 FDA Guides, supra note 27, at 9.
74 Id.
67
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consumers. Accordingly, advertisers of services should focus on the risk of the
potential for deception in the statement. For example, many services have
hidden fees material to a consumer’s decision to purchase the services.75 If any
fees would be deemed a necessary disclosure, it must be included in the
message to avoid liability.76
D. Utilizing the Hyperlink
A hyperlink is a valuable tool for an entity utilizing a CLP.77 A hyperlink is
a link included in the message that allows an interested consumer to be
directed to a separate page that might include the product website or a page of
disclosures. A hyperlink can be in the form of a specific message or a short
sequence of letters that are generally known to be a hyperlink.78 While there is
no exact test to determine the extent of disclosure necessary to prevent a
message from being deemed deceiving,79 the guides suggest to provide at least
some type of disclosure in the message itself and the remaining material
information in a separate page accessed through a hyperlink.80 Regardless of
form, the hyperlink must be easily recognizable by the consumer or it will fail
to prevent the deception intended by its placement.81 However, while a
hyperlink can be a valuable tool in providing non-necessary disclosures, it also
bears the risk of a company placing too much reliance on a hyperlink to satisfy
its disclosure requirements.82

75

Supra note 70 at 10.
Id. at A-4, A-15.
77 Dot Com Disclosures, supra note 38, at 10 (stating that “hyperlinks can provide a useful means to
access disclosures that are not integral to the triggering claim”).
78 Id. at 11; Anjali Dalal, Protecting Hyperlinks and Preserving First Amendment Values on the Internet,
13 U. PA. J. CONST. L. 1017, 1018–19 (2011); Manny D. Pokotilow et al., Internet Linking and Framing Issues,
SM045 ALI-ABA 37, 39 (2007).
79 DOT COM DISCLOSURES, supra note 38, at 7 (stating “there is no set formula for clear and
conspicuous disclosures” and that “it depends on the nature and form of the advertisement.” In evaluating “the
clear and conspicuous requirement,” the FTC provides a list of factors to consider including “the placement of
the disclosure in the advertisement” and “whether the language of the disclosure is understandable to the
intended audience”).
80 Id. at 10 (stating “disclosures that are an integral or inseparable part of a claim should not be
communicated through a hyperlink” but rather “should be placed . . . immediately next to the claim”); Id. at 8,
10; FDA Guides, supra note 27, at 10.
81 Dot Com Disclosures, supra note 38, at 11.
82 See id. at 10–11 (stating information that should not be disclosed via hyperlink includes cost
information, health and safety disclosures or other hidden fees that a consumer would not expect to incur).
76
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E. The Final Determination
While the FDA and FTC guides have helped clarify questions on strategy,
there is still much confusion on how much disclosure is required by an
advertiser utilizing a CLP.83 However, one message is clear. If an advertiser
cannot articulate a message on a CLP that is both effective and fulfills the
disclosure requirements, it should not use that platform.84 If an advertiser does
use a CLP to advertise, it should ensure that it has a detailed risk-management
system in place to guarantee it is communicating a non-misleading message
with adequate disclosure.85
F. Effective Risk Management Systems
While many industries are not required to have a risk management system
(“RMS”) in place, it is strongly recommended by the guides.86 The guides
suggest that the amount of detail required in the RMS should be proportionate
to the amount of marketing that the advertiser would like to use on a CLP.87
Advertisements for products or services associated with a higher risk of
physical or financial harm should include more detailed monitoring systems
than advertisements for products with low risks of harm to the consumer.88
Advertisers that choose to market frequently on a CLP should have more
detailed monitoring systems than advertisers that use other marketing
methods.89 Thus, there is no perfect test to determine how much detail or
resources that an advertiser should direct towards its risk management
program.
A critical problem with inadequate monitoring systems can arise from the
use of a CLP by a third party associated with the entity.90 Should endorsements
83

See id. at 6–7.
FDA Guides, supra note 27, at 5; see Dot Com Disclosures, supra note 38, at 6–7 (stating “if
disclosure is necessary to prevent an advertisement from being deceptive, unfair or otherwise … and it is not
possible to make the disclosure clearly and conspicuously” then either the claim should be modified or the “ad
should not be disseminated.” Moreover, “if a particular platform does not provide an opportunity to make clear
and conspicuous disclosures . . . it should not be used to disseminate advertisements that require such
disclosures”).
85 Fed. Deposit Ins. Corp., FIL-56-2013, Social Media: Consumer Compliance Risk Management
Guidance, FDIC (Dec. 11, 2013), available at https://www.fdic.gov/news/news/financial/2013/fil13056.pdf.
86 Social Media: Consumer Compliance Risk Management Guidance, 78 Fed. Reg. 4,848, 4,850 (Jan. 23,
2013), available at http://www.occ.treas.gov/news-issuances/federal-register/78fr4848.pdf.
87 Id.
88 Id.
89 Id.
90 Advertising Guides, supra note 2 at 53,124.
84
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of a product or service on a CLP be analyzed the same way as if the entity had
communicated the message itself? In other words, should an endorsement by a
third party subject to a contractual relationship with an entity be subject to the
disclosure requirements above?
IV. DISCLOSURES AND THIRD PARTY ENDORSEMENTS
A. Additional Disclosure Requirements for Third Parties
While the guides can be useful in directing an advertiser in marketing its
own product using a CLP, they lack guidance about how disclosures should be
handled by a third party that is being compensated to endorse a product or
service via CLP.91 It would seem contrary to public policy to allow an
advertiser to circumvent the disclosure requirements discussed in the first half
of this Article by paying a celebrity or other third party to endorse its product.
In fact, it would seem that there is an even greater risk of deception when a
third party is promoting a product without revealing that they are benefiting
from their message.92 As discussed above, the increased risk of deception to
consumers requires a greater need for additional disclosure.
B. FTC Guides on Endorsements
In response to the inherent deception that is created with endorsements of
products and services on new media, the FTC revised its guides to include
several examples of how they apply to new forms of consumer-generated
media. These revisions were created to provide a basis for advertisers and
endorsers to comply with the FTC’s provisions and did not purport to cover
every possible use of an endorsement in an advertisement.93 These new
additions were immediately met with criticism; many commenters argued that
it was premature to apply these guides to new media without further discussion
about the scope of liability this would create for advertisers.94 Other
commenters argued that the effect of these revisions would deter advertisers

91 FDA Guidance Limits Flexibility in Social Media Promotional Communications, SKADDEN, ARPS,
SLATE, MEAGHER & FLOM L.L.P. (July 21, 2014), https://www.skadden.com/insights/fda-guidance-limitsflexibility-in-social-media-promotional-communications (last visited Oct. 23, 2015).
92 Guides Concerning the Use of Endorsements and Testimonials in Advertising, supra note 90 at
53,127.
93 Id. at 53,138.
94 Id. at 53,125.
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from using these forums and stunt its growth.95 Nonetheless, the revisions were
added.
While the revisions helped entities understand that third party endorsers can
create liability for the entity or third party through a CLP advertisement, there
are still many questions regarding the amount of disclosure needed by an
endorser and when the endorsers themselves are shielded from liability.96
1. What Is an Endorsement and Who Is an Endorser?
The FTC defines an endorsement as any advertising message or statement
that consumers are likely to believe reflects the opinions, beliefs, or
experiences of a party other than the sponsoring advertiser.97 The guides also
state that it is irrelevant if the message contained in the endorsement is
identical to the views of the advertiser.98 Therefore, the focus is on the
consumer’s perception of the endorsement, rather than the endorser’s
intentions. Commenters argue that focusing on consumer perception in the
realm of endorsements creates inherent uncertainty.99 However, the FTC
dispels that argument by reiterating that the focus on the consumer’s takeaway
is consistent with the approach the Commission uses to determine whether a
practice is deceptive.100
To determine what constitutes an endorsement and who can be classified as
an endorser, the FTC makes the analysis through the eyes of a reasonable
consumer.101 The FTC states that not every person who espouses a beneficial
message about a product or service will be considered an endorser.102 A
statement made by an announcer “who is not familiar to consumers” may not
be an endorsement, unless that announcer is a spokesperson for the advertising

95

Id.
See id. at 53,128 (Stating many commenters criticized the FTC for the lack of guidance of when an
endorser would be liable. They argued it would require “celebrities to educate themselves” on the product,
industry and competition and expose them to liability for claims beyond their expertise or control. They also
argued that the risk of liability would deter them from endorsing products and create a chilling effect. The FTC
claims the new examples featuring celebrities do not create new liability for celebrities but instead serves to
warn them and their advisors about the potential liability associated with their endorsement activities).
97 Id.at 53,124.
98 Id.
99 Id. at 53,124-25.
100 Id. at 53,125.
101 Id.
102 Id. at 53,125-26.
96
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company and is speaking on its behalf.103 However, a “well-recognized”
professional golfer driving a particular brand of golf balls off a tee during a
television commercial would be considered an endorser.104 Other examples
illustrating endorsements suggest that once an individual achieves a level of
recognition, their statements become more susceptible to being characterized
as an endorsement by the FTC.105 However, the FTC has not deemed every use
of social media to discuss a product as an endorsement.
This Article focuses on two types of individuals that would qualify as
endorsers in my interpretation of the guides. The first type of endorser would
be an individual who is highly recognized by the public and has sufficient
influence on consumers (“celebrity endorsers”). Celebrity endorsers include
actors, singers, public figures, politicians, and professional athletes. The
second type of endorser would be any individual who is not well known by the
public, but has a beneficiary relationship with the success of the product or
services (“beneficiary endorsers”). Beneficiary endorsers include high-ranked
employees in a company, or a single individual, who benefit from the product
sales.
a. Disclosing a Material Connection
The FTC requires disclosure of “Material Connections” between an
advertiser and endorser inside each advertisement to prevent consumer
deception.106 This suggests that not every connection between the advertiser
and endorser needs a required disclosure. In order for disclosure to be required,
the connection must be material. It defines a material connection as one that
exists between the endorser and the seller of the advertised product that might
materially affect the credibility of the endorsement.107 Technically, a lowranked employee of a business would fit this definition, and the FTC has
included an example of employees that create liability via online posts.108 This
Article will focus on endorsers who directly benefit from the commission of
sales of a product rather than employees who are working for an hourly wage.
103

Id. at 53,138.
Id.
105 Id. (e.g., “ an announcer who is not familiar to consumers”, “a well-known professional automobile
racing driver”, “a prominent and well-recognized professional golfer”, “well-known entertainer”, “well-known
female comedian”, “well-known celebrity”, “well-known professional tennis player” “who is neither known to
the public”).
106 16 C.F.R. § 255.5.
107 Id.
108 Id. at example 8.
104

12/10/2015 9:17 AM

20

EMORY CORPORATE GOVERNANCE AND ACCOUNTABILITY REVIEW [Vol. 3

b. Additional Disclosure Requirements for Third-Party Endorsements
Section 255.1 of the FTC’s revised guide on endorsements provides
advertisers and endorsers with general considerations for promoting
products.109 Below are two that have generated a lot of criticism, but are useful
in our analysis of the disclosure requirements on a CLP:
(a) “Endorsements must reflect the honest opinions, findings, beliefs, or
experience of the endorser. Furthermore, an endorsement may not convey any
express or implied representation that would be deceptive if made directly by
the advertiser.”110
(d) “Advertisers are subject to liability for false or unsubstantiated statements
made through endorsements, or for failing to disclose material connections
between themselves and their endorsers. Endorsers also may be liable for
statements made in the course of their endorsements.”111
First, the guide makes it clear that an advertisement conveyed by an endorser is
not exempt from the disclosure requirements discussed above.112 Consideration
(a) states that an endorsement cannot state an express or implied representation
that would be deceptive if made directly by the advertiser.113 Consideration (d)
uses the false and unsubstantiated language that we discussed in the first half
of this Article.114 Accordingly, if an endorser decides to make a statement
about a product on a CLP, he or she must also ensure that the message is not
deceptive or misleading.115 But as discussed earlier, an endorsement that is not
representative of what consumers can generally expect to achieve with the
product or service is a deceptive endorsement. In many cases, an opinion or a
testimony of a product would fit this definition.
For example, assume a celebrity that has contracted to promote a brand of
acne medication labeled “ACNE-GONE” tweeted out the following message:
“Acne-gone cleared my acne in 2 days #bumpsbegone #AD”

109
110
111
112
113
114
115

16 C.F.R. § 255.1
Advertising Guides, supra note 2, at § 255.1 (2011).
Id.
16 C.F.R. § 255.1.
Id.
Id.
Id.
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While this is a clear representation of an endorser’s experience with a product,
which is protected under consideration (a), it may still be considered deceptive
if that was not the performance consumers would generally expect to achieve
with the product.116 Accordingly, this statement requires additional disclosure
from the advertiser to avoid deception.117
Advertisers and endorsers can both be subject to liability for misleading
advertisements.118 Thus, advertisers should have some type of regulatory
system in place to avoid liability stemming from third-party statements on a
CLP.119 Companies have expressed concern about being subject to liability for
an endorser’s message, which they did not write.120 They argue that they
should only be liable if they had control over the advertisement.121 The
Commission’s response is that regardless of control, the company initiated the
process that led to the endorsement and should not be shielded from liability
for misleading statements made by endorsers.122
Returning to the example of “Acne-gone,” assume the celebrity was found
to have communicated a deceptive message via Twitter. Under consideration
(a), the celebrity would have a strong defense against being found liable based
on the argument that his or her statement was a truthful reflection of his or her
experience with the product.123 However, while the third-party endorser may
avoid liability from the statement, it does not mean that the advertiser of the
product will also avoid liability.124 The focus is on the injury sustained by the

116

Id.
Id.
118 Id.
119 Advertising Guides, supra note 2 (In its guides the FTC suggests that an employer’s effort to comply
with regulation through institution of policies and practices concerning “social media participation” by its
employees will be a factor in its decision to enforce its regulations in court. They also suggest that an
enforcement action is not likely to be used in the case of a single “rogue” employee who violated established
company policy that adequately covered the conduct in question.)
120 Id. at 53,134-35.
121 Id.
122 Id. at 53,135.
123 16 C.F.R. § 255.5. (Example 2 suggests that a celebrity endorser may avoid liability when only
expressing truthful opinions and personal preferences about a product.)
124 Id.
117
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consumer.125 The Shaggy Defense, “[i]t wasn’t me,”126 is not going to protect
the advertiser in this situation.127
The guides are not clear in regards to when an endorser will be held liable.
The guides state that liability will be determined on a facts and circumstances
basis.128 This Article will describe three different scenarios in which the
endorser may be subject to liability for deceptive messages. All three scenarios
focus on the objective intent of the endorser.
First Scenario
“An endorser should be held liable for failing to adequately disclose the
material connection that he or she has with a product communicated through a
CLP.” 129
The guides clearly suggest that not everybody who endorses a product will
be considered an endorser.130 To be an endorser, one would have to achieve
some level of notoriety, or be in a position to benefit from a consumer buying
that product.131
Celebrity Endorsers
For liability to attach in scenario one, first look to the endorser’s intent.
While there are exceptions to every rule, celebrity endorsers have gained a
high level of influence through hard work and dedication. They are often
conscious of the impact their statements have on their fans, and with influence
comes responsibility. A reasonable person in their position should understand
that advertising a product they are contracted to promote, without adequately
disclosing it, is inherently deceptive to their fans or followers. This reasonable
person determination would be an objective analysis of their intent.132

125

See supra note 122 at 53,125.
See Josh Levin, The Shaggy Defense: America’s Favorite New Legal Term, SLATE (June 7, 2010,
11:59 AM), http://www.slate.com/blogs/browbeat/2010/06/07/the_shaggy_defense_america_s_favorite_new_
legal_term.html.
127 See THE FTC’S ENDORSEMENT GUIDES: WHAT PEOPLE ARE ASKING, FED. TRADE COMM’N, available
at https://www.ftc.gov/system/files/documents/plain-language/pdf-0205-endorsement-guides-faqs_0.pdf.
128 See Guides Concerning the Use of Endorsements and Testimonials in Advertising, 74 16 C.F.R.
§ 255.0(a) (2015), available at http://www.ecfr.gov/cgi-bin/text-idx?SID=de10601c673ac6ac7500291db
fecca38&mc=true&node=pt16.1.255&rgn=div5 .
129 See Id. § 255.1(c) (2015).
130 Advertising Guides, supra note 2 at 53,125–26.
131 Id. at 53,126.
132 Id.
126
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Beneficiary Endorsers
The same analysis used for celebrity endorsers can be applied to
beneficiary endorsers. Under the objective standard, a reasonable person would
understand that endorsing a product or service that he or she directly benefits
from is deceptive to a consumer when not adequately disclosed. Online
forums, product and service review sites, and online marketplaces have a large
influence on a product or service, and with this influence comes the increased
risk of deception.133
For example, David, the creator of the drug Acne-Gone, sold the product to
a well-established business that would be able to produce and distribute it
globally. He not only uses and loves his product, but also loves the 20%
commission that he receives from its sales. Acne-Gone is a new product and
many of the websites that sell this product have limited consumer reviews. In
an effort to jump-start the product’s popularity, David skims the Internet
review sites and anonymously posts the following message on each one:
“This product is amazing. I will never buy another acne cream. I honestly have
only used it a couple days and my face is clearer than it has ever been. I
definitely recommend purchasing this product.”
Regardless of whether David’s statement is true, the message is considered
deceptive according to the guides of the FTC.134 This is a statement that does
not represent the benefits that a consumer should expect with this product.135
David’s intentions and anonymous status may support the argument that he
was not making an advertisement.136 However, surely this message would fit
the definition of an endorsement, and his material connection with the product
would qualify him as an endorser.137 As stated above, an endorsement message
cannot make a representation that would be deceptive if expressly stated by the
advertiser.138 Therefore, the advertiser would be liable for this deceptive

133 See Chayap Katawetawarks & Cheng Lu Wang, Online Shopping Behavior: Influences of Online
Shopping Decision, 1 ASIAN J. BUS. RES. 66, 67 (2011), available at http://www.magscholar.com/joomla/
images/docs/ajbr/ajbrv1n2/Online%20Shopper%20Behavior%20Influences.pdf.
134 See 16 C.F.R. § 255.5 (2015).
135 Id.
136 Advertising Guides, supra note 2.
137 Id. at 255.5.
138 Id. at 255.1.
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statement,139 and David would be liable as an endorser for failing to disclose
his material connection with the product.140
Thus, after using an objective analysis of the endorser’s intent, we find that
endorsers would also be liable for failing to disclose the material connection
that they have with a product or service.141But what about in situations where
they disclose their relationship?
Second Scenario
“An endorser should be held liable when the message communicated on the
CLP is not a reflection of their honest opinions, findings, beliefs, or
experiences.”142
The guides suggest that an endorser can be found liable for making a
deceptive statement about their personal experience with the product or
service.143 An endorsement should reflect the honest opinions, findings,
beliefs, or experiences of the endorser.144
Celebrity Endorsers
Matthew is a professional basketball player, and has an endorsement deal
with a shoe company, “AIR-JOHNS.” Matthew’s Twitter followers are
unaware that Matthew is an endorser of AIR-JOHNS’ shoes. Matthew is told
by his agent that the first set of test results for the new AIR-JOHNS 3s show
that the shoes instantly increased test participants’ vertical jump by three
inches. Matthew was still waiting to receive his pair of AIR-JOHN 3s, when he
posted the following tweet:
The new Air-John 3s are in. Just increased my vertical by 3 inches.
#Flying#AD
Although Matthew has merely repeated results of the test and disclosed his
material connection with the product by using the hashtag #AD, the message is
clearly deceptive to the consumers regardless of his intentions.145 He has not
personally experienced the shoes’ benefits, and the shoes have not increased
139
140
141
142
143
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See id. at § 255.2.

12/10/2015 9:17 AM

2015]

ADEQUATE DISCLOSURES

25

his vertical by 3 inches. By allowing celebrity endorsers to communicate
tweets such as this one, pursuant to contract, or on their own free will,
consumer deception is possible.146
In contrast, suppose Matthew had gained a lot of weight in the last few
months and decided to work on losing weight by jumping up and down one
hundred times a day with his new AIR-JOHNS 3s. As a result, he lost a
substantial amount of weight and the public is begging to know how. A
company that markets a weight loss drug, “SKINNY-MAN”, calls Matthew’s
agent and asks to use a “before and after” picture of Matthew to promote its
product. The company assures Matthew’s agent that it will not put any
messages in the advertisement claiming that Matthew used the product.
Matthew and his agent discuss and agree to allow them to use the pictures in its
advertisement. The company then posts ads throughout Facebook and other
social media sites with the following message:
BUY SKINNY-MAN clinically proven to lose weight fast
Directly under that statement are Matthew’s before and after pictures.
While Matthew is not directly quoted in the advertisement, by agreeing to
allow them to use his pictures he is implicitly endorsing their product. The
deception is clear. Consumers will assume that Matthew used “SKINNYMAN” to lose weight and will buy the product. This implication would violate
general consideration (a), which states that if an endorsement makes a
representation about an experience with a product, then that experience must
be truthful.147 Therefore, while Matthew did not actually use the product, but
consented to the company using his photos, Matthew should be held liable for
the advertiser’s use of his photos.148
Beneficiary Endorsers
Switching the analysis from celebrity endorsers to beneficiary endorsers,
the same result occurs. Allowing beneficiary endorsers to make false claims
about their experiences or opinions on a product, creates a greater risk of
deception.149
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Sam works for AIR-JOHNS and sells AIR-JOHNS products on a
commission basis. Sam goes on YouTube and finds videos that review the new
AIR-JOHNS 3s and writes:
The guy in the video is right. These bad boys helped me finally touch the rim.
They look good too. If anyone wants to buy a pair, I’ll give you a 20%
discount. Email me at Samtheman@gmail.com
Sam has never used the shoes, but immediately receives emails from
consumers to purchase AIR-JOHNS 3s. Under the FTC, Sam’s beneficiary
status qualifies him as an endorser,150 and he therefore violated general
consideration (a) by making a false representation about his experience with
the product. While consumers are not buying this product based on Sam’s
celebrity status, his deceptive marketing strategy has influenced consumers.151
In both the scenarios discussed above, it would seem easy enough for the
endorser to avoid liability by disclosing the connection between the product
and the endorser by using the hashtag #AD. However, the guides do not
specifically state that #AD is sufficient.152 In contrast, the guides suggest that
the use of #AD is not sufficient, and in the context of a CLP, every letter is
important.153 Thus, an additional disclosure is probably needed for an endorser
to avoid liability while conveying a message on a CLP.154
Third Scenario
An endorser should be held liable for failing to disclose other required
disclosures that would make the message deceptive when a reasonable
consumer would feel that disclosure was a “deal breaker.”155
In terms of designating liability, should the endorser be liable for failing to
disclose his connection with the product, any necessary disclosures, and any
hyperlinks to other disclosures required by agencies such as the FTC and
FDA? This is a lot of information for a platform with a character limitation of

150

Id.
Id.
152 The FTC’s Endorsement Guides: What People Are Asking, FED. TRADE COMM’N 12 (May 2015),
https://www.ftc.gov/system/files/documents/plain-language/pdf-0205-endorsement-guides-faqs.pdf.
153 Id.
154 .Com Disclosures: How to Make Effective Disclosures in Digital Advertising, FED. TRADE COMM’N 7
(Mar.
2013),
https://www.ftc.gov/sites/default/files/attachments/press-releases/ftc-staff-revises-onlineadvertising-disclosure-guidelines/130312dotcomdisclosures.pdf [hereinafter Effective Disclosures].
155 Advertising Guides, supra note 2.
151
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140 words or less. As discussed above, the FTC and FDA suggest that
disclosure requirements need to be in the message itself, rather than in a
hyperlink, in order to avoid deception or the possibility that a consumer would
categorize the non-disclosed items as “deal breakers.”156
By the time these disclosures are typed out, there is little room left for the
endorser to convey any message about the product itself. Requiring this
amount of disclosure on a CLP prevents many endorsers from advertising on
these platforms. Further, many endorsers fear the liability attached to
publication of a deceptive statement.157
Consumers may be ultimately injured as well. Consumers often mimic their
role models, and place trust in the services or products used by endorsers.
While it is the opinion of this Article that endorsers should not be held to the
disclosure standards discussed in the FDA and FTC guides, there are still many
situations where additional disclosures should be required in addition to
disclosing a material connection.
To establish the extent of disclosure required in a situation, an objective
standard should be used.158 To do so, consider the standard of a reasonable
consumer to determine if an additional disclosure is a “deal breaker.”159 Would
knowing that additional information materially effect a consumer’s decision to
buy a product or service?
For example, Jake used to be an obese individual. However, he decided to
change his lifestyle and eat three sandwiches a day from the same sandwich
restaurant down the street from his apartment, “SANDWICH”. While each
sandwich was healthier than what Jake had previously been eating, the
sandwiches still contained a high caloric content. In addition to eating the
sandwiches, he jogged for two hours a day and quickly lost a significant
amount of weight. SANDWICH watched his weight loss transition and signed
Jake as a promoter for SANDWICH. Jake subsequently became a popular
public figure, and gained a substantial number of Twitter followers. In
recognition of his achievement he decides to tweet:
Luv all my supporters. Can’t believe I lost 300 lbs eating at SANDWICH. #AD
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In this situation, Jake would not be liable for deceiving consumers under
our first two scenarios. Jake disclosed the material connection between himself
and the product with the hashtag #AD, and lost the weight through his personal
experience of eating at SANDWICH. However, Jake may be liable for failure
to disclose “deal-breakers” because the consumers are under the impression
that SANDWICH is the only reason Jake lost weight. Under an objective
analysis, a reasonable person would understand that jogging two hours a day
also contributed to Jake’s weight loss and would understand that fact to be a
necessary disclosure. Accordingly, in order to avoid the message from being
designated as deceptive, Jake would have to disclose the “deal-breaker” in his
advertisement to avoid personal liability.160
CONCLUSION
The uncertainty created from these guides as they relate to the everexpanding world of social media is apparent. I agree with commenters who
argue that making the endorsement guidance applicable to new online media
was premature. Advertisers and endorsers alike need to know how they should
approach advertising on a CLP, and the risk of consumer deception is higher
than it has ever been in this age of social media. Therefore, acting quickly and
competently is critical in future regulation and guidance.
If there is insufficient regulation, there is a greater risk of consumer
deception by advertisers on social media sites. However, there are many
benefits to consumers and advertisers alike in the use of CLP’s to advertise
products. If there is excessive regulation, there is a risk of advertisers
abandoning CLP’s altogether, which would ultimately injure the consumer.
While concentrating on protecting the consumer, we sometimes forget that the
consumer also has an inherent duty of due diligence.
Regardless of all the confusion surrounding the disclosure requirements
required on a CLP, one thing is certain: marketers will continue to find new
strategies and platforms to advertise their products on platforms that have not
160 See Advertising Guides, supra note 2 at § 255.2. (This scenario is largely based off of the newly added
example 4 and the FTC’s guidance-example 4 illustrates an example of a formerly obese woman claiming in
an advertisement the following statement: “Every day, I drank 2 WeightAway shakes, ate only raw vegetables
and exercised vigorously for six hours at the gym. By the end of six months, I had gone from 250 pounds to
140 pounds.” In its guidance the FTC states that this statement would not be deceiving because she disclosed
her exceptional circumstances under which she achieved her results. However, the FTC states that if she had
merely posted “I lost 110 pounds in six months using WeightAway together with diet and exercise”, this
description would not adequately alert consumers to the remarkable circumstances leading to her weight loss.)
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been specifically addressed by the guides. Therefore, we should come up with
a flexible standard that adapts with our ever-progressing online presence that
continues to educate consumers to use their best judgment regarding product
endorsements.

